• By ICR Secretariat
  • Posted Monday, June 28, 2021

Pfizer's arthritis drug Xeljanz shows lifesaving benefits in hospitalized COVID-19 patients


Pfizer’s BioNTech-partnered COVID-19 vaccine Comirnaty may be getting all the attention these days, but the pharma giant’s anti-inflammatory drug Xeljanz just chalked up a win in treating patients hospitalized with the disease.